Company intelligence / Profile preview

ProteoNic

Leiden, Zuid-Holland, Netherlandsproteonic.nl ↗

Ownership: Private
Employees: ~23
Development stage: Commercial

Overview

ProteoNic’s proprietary expression technologies are commercially deployed to boost yields of complex recombinant proteins—including antibodies and viral vectors—across multiple eukaryotic host systems. The company’s platforms are licensed to biopharma companies for improved manufacturing efficiency and product yield.

Modalities: Recombinant proteinMonoclonal antibodyPolyclonal antibodyFusion protein (including bi-specifics)Viral vector (AAV, lentivirus)
Industry: Contract Manufacturing Organization

Partnerships

GigaGen/Grifols (licensee of the platform for high-yield antibody drug production)

Beyond the preview

Go deeper on ProteoNic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProteoNic.

Explore the full profile